This study was presented, as a poster, at the 4th World Congress of Veterinary Dermatology in San Francisco, California, in August 2000. The abstract, published in Veterinary Dermatology, is referenced as follows: Olivry, T., Rivierre, C., Jackson, H.A. et al. Cyclosporin-A decreases skin lesions and pruritus in dogs with atopic dermatitis: a prednisolone-controlled blinded trial. Veterinary Dermatology 2000; 11 (Suppl 1): 47.
Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial*
Version of Record online: 24 APR 2002
Volume 13, Issue 2, pages 77–87, April 2002
How to Cite
Olivry, T., Rivierre, C., Jackson, H. A., Murphy, K. M., Davidson, G. and Sousa, C. A. (2002), Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Veterinary Dermatology, 13: 77–87. doi: 10.1046/j.1365-3164.2002.00283.x
- Issue online: 24 APR 2002
- Version of Record online: 24 APR 2002
- (Received 7 July 2001; accepted 30 August 2001)
- atopic dermatitis;
- cyclosporin A;
- randomized controlled trial
Abstract During the last decade, oral cyclosporin (CsA) has proven to be effective, in randomized controlled trials, for the treatment of atopic dermatitis (AD) in human patients. The purpose of this blinded randomized controlled trial was to test the hypothesis that CsA was successful in reducing the gravity of clinical signs of AD in dogs. Thirty dogs with nonseasonal AD were randomly allocated to receive an oral solution of either NEORAL CsA (5 mg kg−1) or prednisolone (0.5 mg kg−1) once daily for 6 weeks. Before, and 3 and 6 weeks after therapy, skin lesions were graded by clinicians using the Canine AD Extent and Severity Index (CADESI). Pruritus was assessed by the owners using a visual analog scale (PVAS). In both groups, CADESI and PVAS values were significantly lower at 6 weeks post treatment than before the initiation of therapy (Friedman test, P < 0.0004). The percentage reductions in CADESI and PVAS values from baseline were not statistically different between groups (Mann–Whitney test, P > 0.3). In this experiment, the tolerability and safety of oral CsA and prednisolone appeared similar. One-fifth of dogs given oral CsA occasionally developed diarrhoea or soft stools. One dog that was given CsA developed a generalized papillomatous skin eruption during the second half of the trial. Our study provides randomized controlled trial evidence that CsA reduces the severity of clinical signs in dogs with nonseasonal AD. Moreover, the anti-allergic efficacy of CsA appears comparable with that of prednisolone. We propose that oral CsA should be considered as a valuable alternative to glucocorticoid therapy in dogs with AD.